Back to results
US 2026/0234236 A1Published application
Canine antibodies to canine il-13
AssigneeIntervet Inc.
InventorsMohamad MORSEY, Zhisong QIAO, Seth D. STAUFFER, Yuanzheng ZHANG
Life of this patent
Estimating the term…
Abstract
The present invention provides canine antibodies that bind to canine interleukin-13 (canine IL-13) that have a high binding affinity for canine IL-13 and that can block the binding of canine IL-13 to the canine Type II heterodimer IL-4 receptor. The present invention also provides methods of using the antibodies of the present invention in the treatment of atopic dermatitis in dogs.
Claims29
A canine antibody or antigen binding fragment thereof, that binds canine interleukin-13 (cIL-13), wherein the antibody comprises a heavy chain and a light chain that together comprise a set of six complementary determining regions (CDRs), three of which are heavy chain CDRs:
- CDR heavy 1 (HCDR1), CDR heavy 2 (HCDR2) and CDR heavy 3 (HCDR3) and three of which are light chain CDRs:
- CDR light 1 (LCDR1), CDR light 2 (LCDR2), and CDR light 3 (LCDR3);
- wherein each CDR comprises an amino acid sequence;
- and
- wherein the set of six CDRs are selected from the group of sets consisting of (i), (ii), (iii), (iv), (v), (vi), (vii), (viii) and (ix);
- wherein for set (i):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 150;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 151;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 152;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 153;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 235;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 155;
- wherein for set (ii):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 150;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 151;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 152;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 153;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 154;
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 155;
- wherein for set (iii)
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 126;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 127;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 128;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 129;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 130;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 131;
- wherein for set (iv):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 132;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 133;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 134;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 135;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 136;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 137;
- wherein for set (v):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 138;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 139;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 140;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 141;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 142;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 143;
- wherein for set (vi)
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 144;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 145;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 146;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 147;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 148;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 149;
- wherein for set (vii)
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 120;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 121;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 122;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 123;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 124;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 125;
- and
- wherein for set (viii)
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 114;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 115;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 116;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 117;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 118;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 119;
- wherein for set (ix)
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 248;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 249;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 250;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 251;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 252;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 253;
- wherein the canine antibody or antigen binding fragment thereof bind to cIL-13.
129 more elements
(canceled)
(canceled)
-20. (canceled)
-23. (canceled)
-26. (canceled)
-29. (canceled)
(canceled)
A single-chain Fv (scFv) antibody comprising a set of six complementary determining regions (CDRs), three of which are heavy chain CDRs:
- CDR heavy 1 (HCDR1), CDR heavy 2 (HCDR2) and CDR heavy 3 (HCDR3) and three of which are light chain CDRs:
- CDR light 1 (LCDR1), CDR light 2 (LCDR2), and CDR light 3 (LCDR3);
- wherein each CDR comprises an amino acid sequence;
- and wherein the set of six CDRs is selected from the group of sets consisting of (i), (ii), (iii), (iv), (v), (vi), (vii), (viii) and set (ix);
- wherein for set (i):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 114;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 115;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 116;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 117;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 118;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 119;
- wherein for set (ii):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 120;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 121;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 122;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 123;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 124;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 125;
- wherein for set (iii)
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 126;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 127;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 128;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 129;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 130;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 131;
- wherein for set (iv):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 132;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 133;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 134;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 135;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 136;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 137;
- wherein for set (v):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 138;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 139;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 140;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 141;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 142;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 143;
- wherein for set (vi)
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 144;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 145;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 146;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 147;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 148;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 149;
- wherein for set (vii)
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 150;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 151;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 152;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 153;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 235;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 155;
- wherein for set (viii)
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 150;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 151;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 152;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 153;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 154;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 155;
- wherein for set (ix)
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 248;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 249;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 250;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 251;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 252;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 253;
- and
- wherein the scFv antibody binds cIL-13.
129 more elements
-35. (canceled)
Dependencies are inferred from the claim text.